 To combine Brentuximab Vedotin with Dexamethasone, AraC and Cisplatin DHAP chemotherapy in patients with Hodgkin lymphoma HL refractory to first line chemotherapy or in first relapse is expected to induce a significantly higher metabolic complete remission CR rate prior to consolidation with BEAM, as judged by FDG 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose-PET negativity. This will be compared with published data on DHAP salvage only. Increasing the metabolic CR rate prior to consolidation with high dose chemotherapy and autologous stem cell transplantation ASCT is expected to improve progression free survival PFS and overall survival OS. 